Banyu Launches Merck’s Isentress HIV Drug In Japan
This article was originally published in PharmAsia News
Banyu Pharmaceutical launched in Japan the HIV treatment Isentress (raltegravir), the only drug of its kind for blocking the virus that causes AIDS. The drug works by inserting viral DNA into human DNA to inhibit the integrase enzyme. Banyu is a wholly owned subsidiary of U.S. drug maker Merck. The drug also can help HIV-infected people who have developed a resistance to other drugs. (Click here for more - a subscription may be required
You may also be interested in...
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.
GSK is transferring technology to make its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower cost of the vaccine for such programs
Rules covering OTC medical devices, herbals and online activities have been added for the first time to the Irish Pharmaceutical Healthcare Association's Self-Care Advertising Code.